[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,569,522
  • Shares Outstanding, K 86,841
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,200 K
  • EBIT $ -202 M
  • EBITDA $ -213 M
  • 60-Month Beta 3.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.87

Options Overview Details

View History
  • Implied Volatility 72.10% (+0.14%)
  • Historical Volatility 74.96%
  • IV Percentile 2%
  • IV Rank 7.46%
  • IV High 222.63% on 09/16/25
  • IV Low 59.96% on 08/18/25
  • Expected Move (DTE 34) 12.04 (16.07%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 431
  • Volume Avg (30-Day) 368
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 9,004
  • Open Int (30-Day) 8,997
  • Expected Range 62.88 to 86.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 6
  • High Estimate $-0.59
  • Low Estimate $-0.80
  • Prior Year $-0.49
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.88 +12.02%
on 04/16/26
78.80 -4.92%
on 05/11/26
+5.93 (+8.60%)
since 04/15/26
3-Month
34.96 +114.30%
on 02/17/26
78.80 -4.92%
on 05/11/26
+38.29 (+104.53%)
since 02/13/26
52-Week
13.93 +437.83%
on 06/17/25
78.80 -4.92%
on 05/11/26
+60.38 (+415.27%)
since 05/15/25

Most Recent Stories

More News
Spyre Therapeutics: Q1 Earnings Snapshot

Spyre Therapeutics: Q1 Earnings Snapshot

SYRE : 74.92 (-0.96%)
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class  ...

SYRE : 74.92 (-0.96%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and...

SYRE : 74.92 (-0.96%)
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 74.92 (-0.96%)
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...

SYRE : 74.92 (-0.96%)
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...

SYRE : 74.92 (-0.96%)
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY001 met its primary endpoint with a  statistically significant reduction of 9.2 points (p

SYRE : 74.92 (-0.96%)
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026

WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 74.92 (-0.96%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 74.92 (-0.96%)
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriatic arthritis (PsA) and axial...

SYRE : 74.92 (-0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based...

See More

Key Turning Points

3rd Resistance Point 81.69
2nd Resistance Point 79.39
1st Resistance Point 77.15
Last Price 74.92
1st Support Level 72.61
2nd Support Level 70.31
3rd Support Level 68.07

See More

52-Week High 78.80
Last Price 74.92
Fibonacci 61.8% 54.02
Fibonacci 50% 46.37
Fibonacci 38.2% 38.71
52-Week Low 13.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.